S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NYSE:GSK

GlaxoSmithKline Stock Forecast, Price & News

$34.91
+0.63 (+1.84 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$34.33
Now: $34.91
$34.97
50-Day Range
$33.61
MA: $36.18
$39.24
52-Week Range
$31.43
Now: $34.91
$43.18
Volume6.45 million shs
Average Volume6.36 million shs
Market Capitalization$87.57 billion
P/E Ratio10.74
Dividend Yield7.24%
Beta0.67
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
GlaxoSmithKline logo

Headlines

Top 15 Pharmaceutical Companies With Highest R&D Spending
February 24, 2021 |  finance.yahoo.com
Glaxo’s Supplier Plans Pakistan’s Largest Pharma IPO
February 19, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-8047-5000
Employees99,437
Year Founded2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.10 billion
Cash Flow$4.02 per share
Book Value$9.40 per share

Profitability

Net Income$5.93 billion

Miscellaneous

Outstanding Shares2,508,520,000
Market Cap$87.57 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.11 out of 5 stars

Medical Sector

944th out of 1,969 stocks

Pharmaceutical Preparations Industry

445th out of 771 stocks

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
$34.91
+0.63 (+1.84 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

Is GlaxoSmithKline a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last twelve months. There are currently 3 sell ratings, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GlaxoSmithKline stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View analyst ratings for GlaxoSmithKline
or view top-rated stocks.

What stocks does MarketBeat like better than GlaxoSmithKline?

Wall Street analysts have given GlaxoSmithKline a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GlaxoSmithKline wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 19,410,000 shares, an increase of 37.1% from the January 28th total of 14,160,000 shares. Based on an average daily trading volume, of 5,410,000 shares, the days-to-cover ratio is currently 3.6 days.
View GlaxoSmithKline's Short Interest
.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for GlaxoSmithKline
.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) released its quarterly earnings data on Tuesday, February, 2nd. The pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.64 by $0.02. The pharmaceutical company had revenue of $8.74 billion for the quarter, compared to the consensus estimate of $8.71 billion. GlaxoSmithKline had a net margin of 18.50% and a trailing twelve-month return on equity of 29.60%. The company's quarterly revenue was down 1.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.39 EPS.
View GlaxoSmithKline's earnings history
.

How has GlaxoSmithKline's stock been impacted by COVID-19 (Coronavirus)?

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GSK shares have decreased by 12.4% and is now trading at $34.91.
View which stocks have been most impacted by COVID-19
.

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Thursday, February 4th. Shareholders of record on Friday, February 19th will be paid a dividend of $0.628 per share on Thursday, April 8th. This represents a $2.51 annualized dividend and a dividend yield of 7.20%. The ex-dividend date is Thursday, February 18th. This is a positive change from GlaxoSmithKline's previous quarterly dividend of $0.50.
View GlaxoSmithKline's dividend history
.

Is GlaxoSmithKline a good dividend stock?

GlaxoSmithKline pays an annual dividend of $2.48 per share and currently has a dividend yield of 7.24%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. GlaxoSmithKline does not yet have a strock track record of dividend growth. The dividend payout ratio of GlaxoSmithKline is 78.23%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on EPS estimates, GlaxoSmithKline will have a dividend payout ratio of 80.52% in the coming year. This indicates that GlaxoSmithKline may not be able to sustain their current dividend.
View GlaxoSmithKline's dividend history.

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the following people:
  • Ms. Emma N. Walmsley, CEO & Director (Age 51)
  • Mr. Iain James Mackay, CFO & Exec. Director (Age 59)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 58)
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 60)
  • Ms. Sarah Elton-Farr, Head of Investor Relations
  • Mr. Nick Hirons, Sr. VP of Global Ethics & Compliance
  • Mr. James Ford, Sr. VP & Gen. Counsel
  • Ms. Sally Jackson, Sr. VP of Global Communications & CEO Office
  • Ms. Diana Conrad, Sr. VP of HR
  • Mr. David Simon Redfern, Chief Strategy Officer (Age 55)

Who are some of GlaxoSmithKline's key competitors?

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), The Walt Disney (DIS) and NVIDIA (NVDA).

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a number of institutional and retail investors. Top institutional investors include Dodge & Cox (2.51%), Price T Rowe Associates Inc. MD (0.66%), Fisher Asset Management LLC (0.66%), Renaissance Technologies LLC (0.57%), Black Creek Investment Management Inc. (0.30%) and Boston Partners (0.22%).
View institutional ownership trends for GlaxoSmithKline
.

Which institutional investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Price T Rowe Associates Inc. MD, Eaton Vance Management, Eaton Vance Management, Schafer Cullen Capital Management Inc, BlackRock Inc., Truist Financial Corp, and HighPoint Advisor Group LLC.
View insider buying and selling activity for GlaxoSmithKline
or view top insider-selling stocks.

Which institutional investors are buying GlaxoSmithKline stock?

GSK stock was bought by a variety of institutional investors in the last quarter, including Dodge & Cox, Nuveen Asset Management LLC, Vontobel Holding Ltd., Black Creek Investment Management Inc., Norges Bank, Brandywine Global Investment Management LLC, Equity Investment Corp, and Morgan Stanley.
View insider buying and selling activity for GlaxoSmithKline
or or view top insider-buying stocks.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $34.91.

How much money does GlaxoSmithKline make?

GlaxoSmithKline has a market capitalization of $87.57 billion and generates $43.10 billion in revenue each year. The pharmaceutical company earns $5.93 billion in net income (profit) each year or $3.17 on an earnings per share basis.

How many employees does GlaxoSmithKline have?

GlaxoSmithKline employs 99,437 workers across the globe.

When was GlaxoSmithKline founded?

GlaxoSmithKline was founded in 2000.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is www.gsk.com.

Where are GlaxoSmithKline's headquarters?

GlaxoSmithKline is headquartered at 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.